伦敦金属交易所收购机会(纳斯达克：LMAO)与阿波罗内外科(纳斯达克：APEN)关键比较

Apollo Endosurgery (NASDAQ:APEN – Get Rating) and LMF Acquisition Opportunities (NASDAQ:LMAO – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

Insider and Institutional Ownership

94.6% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 79.3% of LMF Acquisition Opportunities shares are owned by institutional investors. 26.2% of Apollo Endosurgery shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

This table compares Apollo Endosurgery and LMF Acquisition Opportunities' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Apollo Endosurgery and LMF Acquisition Opportunities' top-line revenue, earnings per share (EPS) and valuation.

LMF Acquisition Opportunities has lower revenue, but higher earnings than Apollo Endosurgery.

Analyst Ratings

This is a summary of current recommendations and price targets for Apollo Endosurgery and LMF Acquisition Opportunities, as reported by MarketBeat.

Apollo Endosurgery presently has a consensus target price of $12.80, suggesting a potential upside of 242.25%. Given Apollo Endosurgery's higher possible upside, equities research analysts clearly believe Apollo Endosurgery is more favorable than LMF Acquisition Opportunities.

Risk & Volatility

Apollo Endosurgery has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, LMF Acquisition Opportunities has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500.

Summary

Apollo Endosurgery beats LMF Acquisition Opportunities on 6 of the 10 factors compared between the two stocks.

About Apollo Endosurgery (Get Rating)

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

About LMF Acquisition Opportunities (Get Rating)

LMF Acquisition Opportunities, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Tampa, Florida.

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.